JP2024533109A5 - - Google Patents
Info
- Publication number
- JP2024533109A5 JP2024533109A5 JP2024513689A JP2024513689A JP2024533109A5 JP 2024533109 A5 JP2024533109 A5 JP 2024533109A5 JP 2024513689 A JP2024513689 A JP 2024513689A JP 2024513689 A JP2024513689 A JP 2024513689A JP 2024533109 A5 JP2024533109 A5 JP 2024533109A5
- Authority
- JP
- Japan
- Prior art keywords
- ada
- recombinant protein
- cell according
- human
- operably linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163238927P | 2021-08-31 | 2021-08-31 | |
| US63/238,927 | 2021-08-31 | ||
| US202263355396P | 2022-06-24 | 2022-06-24 | |
| US63/355,396 | 2022-06-24 | ||
| PCT/US2022/042193 WO2023034408A1 (en) | 2021-08-31 | 2022-08-31 | Chimeric antigen receptor (car) t cell therapy platform |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024533109A JP2024533109A (ja) | 2024-09-12 |
| JP2024533109A5 true JP2024533109A5 (cg-RX-API-DMAC7.html) | 2025-09-04 |
Family
ID=85411600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024513689A Pending JP2024533109A (ja) | 2021-08-31 | 2022-08-31 | キメラ抗原受容体(car)t細胞療法プラットフォーム |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20240350546A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4396341A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024533109A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240050428A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023034408A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20250134998A1 (en) * | 2021-08-30 | 2025-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | T cells with cell-surface expression of adenosine deaminase and uses thereof |
| WO2026035304A1 (en) * | 2024-04-08 | 2026-02-12 | Gemini Corp. | Medical modeling architecture, intelligence and methods |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2015332533B2 (en) * | 2014-10-14 | 2018-08-30 | Halozyme, Inc. | Compositions of adenosine deaminase-2 (ADA2), variants thereof and methods of using same |
| CN112672753B (zh) * | 2018-07-09 | 2025-07-08 | 普瑞赛格恩公司 | 融合构建体及其使用方法 |
| EP3893923A2 (en) * | 2018-12-14 | 2021-10-20 | Autolus Limited | Cell |
| US12600971B2 (en) * | 2019-02-13 | 2026-04-14 | Beam Therapeutics Inc. | Modified immune cells having adenosine deaminase base editors for modifying a nucleobase in a target sequence |
| US20250134998A1 (en) * | 2021-08-30 | 2025-05-01 | The Board Of Trustees Of The Leland Stanford Junior University | T cells with cell-surface expression of adenosine deaminase and uses thereof |
-
2022
- 2022-08-31 EP EP22865500.7A patent/EP4396341A4/en active Pending
- 2022-08-31 US US18/686,868 patent/US20240350546A1/en active Pending
- 2022-08-31 KR KR1020247010529A patent/KR20240050428A/ko active Pending
- 2022-08-31 JP JP2024513689A patent/JP2024533109A/ja active Pending
- 2022-08-31 WO PCT/US2022/042193 patent/WO2023034408A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2276735T3 (es) | Anticuerpos fv multimericos de cadena sencilla en tandem. | |
| Morrison | In vitro antibodies: strategies for production and application | |
| Pavlinkova et al. | Pharmacokinetics and biodistribution of engineered single-chain antibody constructs of MAb CC49 in colon carcinoma xenografts | |
| US5767260A (en) | Antigen-binding fusion proteins | |
| EP3057991B1 (en) | Chimeric antigen receptor t cell switches and uses thereof | |
| JP5938473B2 (ja) | 多価抗原結合Fv分子 | |
| ES2199941T3 (es) | Anticuerpos monoclonales contra el receptor de la interferona, con actividad neutralizadora contra el interferon de tipo j. | |
| CA3148621A1 (en) | Compositions and methods comprising protease-activated therapeutic agents | |
| JP2019137675A5 (cg-RX-API-DMAC7.html) | ||
| JP2009523459A5 (cg-RX-API-DMAC7.html) | ||
| JP2010522701A5 (cg-RX-API-DMAC7.html) | ||
| JP2001095566A (ja) | サイトカインの免疫複合体 | |
| JP2003292458A (ja) | 細胞毒性剤治療 | |
| CN117255691A (zh) | 干扰素前药、制备方法及应用 | |
| JP7247113B2 (ja) | ミクログリアの活性化を抑制する方法 | |
| WO2021082573A1 (zh) | 抗il-4r单域抗体及其应用 | |
| US12410225B2 (en) | Modulation of dendritic cell lineages | |
| CN115698059A (zh) | 使用抗bet v 1抗体治疗过敏的方法 | |
| JP2013193995A (ja) | 特発性炎症性筋疾患の予防又は治療剤 | |
| CN103179987A (zh) | 抑制p24蛋白产生或促进p24蛋白消除的方法和药物组合物 | |
| JPWO2006046661A1 (ja) | インターロイキン−6阻害剤 | |
| JP2022513321A5 (cg-RX-API-DMAC7.html) | ||
| CN120399078B (zh) | 靶向cd117的纳米抗体及其应用 | |
| Xiang | Targeting cytokines to tumors to induce active antitumor immune responses by recombinant fusion proteins | |
| JP2024527571A (ja) | インターロイキン-1アルファキメラタンパク質 |